Core Viewpoint - The approval of the drug registration certificate for Oseltamivir Phosphate Capsules by the National Medical Products Administration is a significant milestone for the company, enhancing its product portfolio and production capacity, which is expected to positively impact future operations [1] Group 1 - The company announced that its wholly-owned subsidiary, Shaanxi Buchang High-tech Pharmaceutical Co., Ltd., has received the drug registration certificate for Oseltamivir Phosphate Capsules [1] - Oseltamivir Phosphate Capsules are primarily used for the treatment of influenza A and B in adults and children aged one year and older, as well as for prevention in adults and adolescents aged 13 years and older [1] - The registration of this drug is beneficial for the company to optimize its product structure and maintain stable production capacity to meet market demand [1]

Core Viewpoint - Company announced that its wholly-owned subsidiary, Shaanxi Buchang High-tech Pharmaceutical Co., Ltd., has received the drug registration certificate for Oseltamivir Phosphate Capsules from the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Product Approval - The approved drug is primarily used for the treatment of influenza A and B in adults and children aged 1 year and older, as well as for the prevention of influenza A and B in adults and adolescents aged 13 years and older [1] Group 2: Market Potential - The annual sales figures for urban retail pharmacies in China for the years 2022, 2023, and 2024 are projected to be 152 million, 824 million, and 776 million respectively, indicating a growing market for influenza treatments [1] - The company has invested approximately 12.96 million in research and development for this project as of the announcement date [1]

Market Overview - The Chinese medicine sector experienced a decline of 0.36% on August 28, with Xintian Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Buchang Pharmaceutical (603858) with a closing price of 20.02, up 5.59% and a trading volume of 325,000 shares, totaling 654 million yuan [1] - Tianmu Pharmaceutical (600671) closed at 20.40, up 5.37% with a trading volume of 159,300 shares, totaling 324 million yuan [1] - Jilin Aodong (000623) closed at 20.34, up 1.75% with a trading volume of 239,000 shares, totaling 479 million yuan [1] - Conversely, significant decliners included: - Xinda Pharmaceutical (002873) with a closing price of 12.00, down 4.76% and a trading volume of 304,000 shares, totaling 364 million yuan [2] - Qidi Pharmaceutical (000590) closed at 12.22, down 4.61% with a trading volume of 221,600 shares, totaling 274 million yuan [2] - Kangjia Pharmaceutical (600557) closed at 17.22, down 4.39% with a trading volume of 313,700 shares, totaling 537 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 1.134 billion yuan from institutional investors, while retail investors contributed a net inflow of 930 million yuan [2] - Key stocks with significant capital flow included: - Zhendong Pharmaceutical (300158) with a net inflow of 67.58 million yuan from institutional investors [3] - Jilin Aodong (000623) with a net inflow of 13.62 million yuan from institutional investors [3] - Tianmu Pharmaceutical (600671) with a net inflow of 7.33 million yuan from institutional investors [3]

按申万行业统计，步长制药所属的医药生物行业共有49家公司公布了2025半年度分配方案，派现金额最 多的是药明康德，派现金额为10.03亿元，其次是东阿阿胶、华润三九，派现金额分别为8.17亿元、7.51 亿元。（数据宝） 2025半年度医药生物行业分红排名 | 代码 | 简称 | 每10股送转 | 每10股派现 | 派现金额（万 | 派现占净利润比例 | 股息率 | | --- | --- | --- | --- | --- | --- | --- | | | | （股） | （元） | 元） | （%） | （%） | 8月27日步长制药发布2025半年度分配预案，拟10派3.9元（含税），预计派现金额合计为4.11亿元。派 现额占净利润比例为65.52%，以该股2025半年度成交均价计算，股息率为2.52%。这是公司上市以来， 累计第9次派现。 公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2025.06.30 | 10派3.9元（含税） | 4.11 | 2.52 | | 2023.12.31 ...

Group 1 - The company reported a revenue of 5,663,836,253.89 yuan for the first half of 2025, representing a year-on-year growth of 4.27% [1] - The net profit attributable to shareholders of the listed company was 627,701,257.33 yuan, showing a significant year-on-year increase of 171.24% [1]

Core Viewpoint - The company, Buchang Pharmaceutical, announced the approval of several proposals, including the 2025 semi-annual report and summary, during the 30th meeting of its fifth board of directors [2] Group 1 - The company held its fifth board of directors' 30th meeting on August 27 [2] - The meeting resulted in the approval of the 2025 semi-annual report and summary [2]

Core Viewpoint - The company, Buchang Pharma, announced the approval of several proposals, including the 2025 semi-annual report and summary, during the seventh meeting of its fifth supervisory board [2] Group 1 - The supervisory board meeting was held on August 27, where multiple proposals were reviewed and approved [2]

Core Insights - The company reported a revenue of 5.664 billion yuan for the first half of 2025, representing a year-on-year growth of 4.27% [1][2] - The net profit attributable to shareholders reached 627 million yuan, showing a significant increase of 171.24% compared to the same period last year [1][2] - The net cash flow from operating activities was 959 million yuan, reflecting a growth of 92.87% year-on-year [1][2] Financial Performance - Revenue for the first half of 2025: 5.664 billion yuan, up 4.27% from 5.432 billion yuan in the same period last year [2] - Total profit for the period was approximately 750 million yuan, an increase of 85.55% from around 404 million yuan [2] - Net profit attributable to shareholders: 627 million yuan, up from 231 million yuan, marking a 171.24% increase [2] - Net profit after deducting non-recurring gains and losses: 619 million yuan, up 180.04% from 221 million yuan [2] - Net cash flow from operating activities: 959 million yuan, compared to 497 million yuan last year, a growth of 92.87% [2] Asset and Equity Position - Net assets attributable to shareholders at the end of the reporting period were approximately 10.744 billion yuan, a 5.16% increase from 10.216 billion yuan at the end of the previous year [2] - Total assets amounted to about 19.977 billion yuan, reflecting a 3.35% increase from 19.329 billion yuan [2] Leadership Information - Zhao Chao, the company's president, holds a PhD in economics from Xi'an Jiaotong University and has been in various leadership roles within the company [3] - Zhao Chao's compensation from 2020 to 2024 has been relatively stable, with figures around 231.1 thousand yuan in 2024 [4]

Core Viewpoint - The company reported a significant increase in net profit and revenue for the first half of 2025, indicating strong financial performance and growth potential in the pharmaceutical industry [1] Financial Performance - The company achieved an operating revenue of 5.664 billion yuan, representing a year-on-year growth of 4.27% [1] - The net profit attributable to shareholders reached 628 million yuan, showing a remarkable year-on-year increase of 171.24% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 619 million yuan, reflecting a year-on-year growth of 180.04% [1]

Core Points - The company plans to distribute a cash dividend of RMB 3.90 per 10 shares to all shareholders based on the total share capital as of the record date for the distribution [1][2] - The total cash dividend to be distributed amounts to RMB 411,281,692.38 (including tax) [2] - The profit distribution plan does not involve capital reserve transfer to increase share capital or issuance of bonus shares [1][2] Company Procedures - The board of directors approved the profit distribution plan during the 30th meeting of the fifth board on August 27, 2025, without needing to submit it to the shareholders' meeting due to prior authorization [2] - The supervisory board also approved the profit distribution plan on the same date, confirming its compliance with relevant laws and regulations [2] Additional Information - The profit distribution plan considers the company's operating model and profitability, ensuring it does not significantly impact the company's cash flow or earnings per share [2] - The specific date for the implementation of the profit distribution will be clarified in a subsequent announcement [2]